Prognostic influence of tumor-infiltrating mast cells in follicular lymphoma patients treated with rituximab and CHOP.

@article{citeulike:2460687, abstract = {Gene expression profiling and immunohistochemical studies have demonstrated that nonmalignant tumor infiltrating inflammatory cells contribute to clinical outcome in FL patients. Particularly, tumor associated macrophage (TAM) content correlates with longer survival rates after immunochemotherapy. Here we investigated the prognostic importance of tumor-associated mast cells (MCs) and their relation to TAMs in FL patients treated with combination of rituximab (R) and CHOP chemotherapy. Of the 98 patients, 70 received R-CHOP at diagnosis and 28 at relapse. According to Kaplan Meier estimates, the patients with high MC content had a worse 4-year progression free survival (PFS) after R-CHOP therapy (34\% vs 74\%, p=0.002). The adverse prognostic value of MCs was seen both for the patients treated at diagnosis and at relapse, whereas no such impact on PFS was observed for the control patients treated with chemotherapy only (p=0.4). When the TAM related PFS was analyzed separately in patients with high and low MC contents, the positive prognostic effect of TAM was seen only in patients with few MCs. Taken together, the data demonstrate that high MC score is associated with unfavorable prognosis and it eliminates the positive prognostic value of TAMs in FL patients treated with immunochemotherapy.}, address = {Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.}, author = {Taskinen, Minna and Karjalainen-Lindsberg, Marja-Liisa L. and Leppa, Sirpa }, citeulike-article-id = {2460687}, doi = {10.1182/blood-2007-11-125823}, issn = {0006-4971}, journal = {Blood}, month = {February}, posted-at = {2008-03-03 11:32:37}, priority = {2}, title = {Prognostic influence of tumor-infiltrating mast cells in follicular lymphoma patients treated with rituximab and CHOP.}, url = {http://dx.doi.org/10.1182/blood-2007-11-125823}, year = {2008} }

TY - JOUR ID - citeulike:2460687 L3 - citeulike-article-id:2460687 TI - Prognostic influence of tumor-infiltrating mast cells in follicular lymphoma patients treated with rituximab and CHOP. JF - Blood AD - Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. SN - 0006-4971 N2 - Gene expression profiling and immunohistochemical studies have demonstrated that nonmalignant tumor infiltrating inflammatory cells contribute to clinical outcome in FL patients. Particularly, tumor associated macrophage (TAM) content correlates with longer survival rates after immunochemotherapy. Here we investigated the prognostic importance of tumor-associated mast cells (MCs) and their relation to TAMs in FL patients treated with combination of rituximab (R) and CHOP chemotherapy. Of the 98 patients, 70 received R-CHOP at diagnosis and 28 at relapse. According to Kaplan Meier estimates, the patients with high MC content had a worse 4-year progression free survival (PFS) after R-CHOP therapy (34% vs 74%, p=0.002). The adverse prognostic value of MCs was seen both for the patients treated at diagnosis and at relapse, whereas no such impact on PFS was observed for the control patients treated with chemotherapy only (p=0.4). When the TAM related PFS was analyzed separately in patients with high and low MC contents, the positive prognostic effect of TAM was seen only in patients with few MCs. Taken together, the data demonstrate that high MC score is associated with unfavorable prognosis and it eliminates the positive prognostic value of TAMs in FL patients treated with immunochemotherapy. AU - Taskinen, Minna AU - Karjalainen-Lindsberg, Marja-Liisa AU - Leppa, Sirpa PY - 2008/02/28/ UR - http://dx.doi.org/10.1182/blood-2007-11-125823 ER -